|
|
|
11-50 employees
View all
|
|
Pharmaceuticals
|
|
Joukahaisenkatu 6, Turku, FI
|
|
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the Company's investigational intravenous interferon beta-1a is a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
|
Faron Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Faron email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Faron customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.